Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention

European Heart Journal

Volumn 24, Issue 21, 2003, Pages 1912-1919

  Lu, Tse Min ^a   Ding, Yu An ^a,b   Lin, Shing Jong ^a   Lee, Wen Shin ^a   Tai, Ho Charng ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Asymmetrica dimethylarginine; Nitric oxide; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRATE;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVASCULARIZATION; RISK ASSESSMENT; STABLE ANGINA PECTORIS; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARGININE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0142209281     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.08.013     Document Type: Article

References (37)

1. Janero DR, Ewing JF. Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Radical Bio Med 2000;29:1199-221.
2. Schächinber V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
3. e·mono-, di-, and trimethyllysine, glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970;245:5751-8.
4. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
5. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43:542-8.
6. Böger RH, Bode-Böger SM, Szuba A et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7.
7. Surdacki A, Nowichi M, Sandmann J et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-8.
8. Abbasi F, Asagmi T, Cooke JP et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-3.
9. Lu TM, Ding YA, Charng MJ et al. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 2003;26:458-64.
10. Zoccali C, Bode-Böger SM, Mallamaci F et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
11. Valkonen VP, Pälvä H, Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
12. Fiskerstrand T, Refsum H, Kvalheim G et al. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993;39:263-71.
13. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
14. Lefroy DC, Crake T, Uren NG et al. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993;88:43-54.
15. Quyyumi AA, Dakak N, Andrews NP et al. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest 1995;95:1747-55.
16. Kubes P, Suzuki M, Ganger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
17. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic gaunosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
18. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-8.
19. Sarkar R, Meinberg EG, Stanley JC et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996;78:225-30.
20. Le Tourneau T, Van Belle E, Corseaux D et al. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. J Am Call Cordial 1999;33:876-82.
21. Vermeersch P, Nong Z, Stabile E et al. L-arginine administration reduces neointimal formation after stent injury in rats by a nitric oxide-mediated mechanism. Arterioscler Thromb Vasc Biol 2001;21:1604-9.
22. Janssens S, Flaherty D, Nong Z et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointimal formation after balloon injury in rats. Circulation 1998;97:1274-81.
23. Varenne O, Pislaru S, Gillijns H et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998;98:919-26.
24. Lundman P, Eriksson MJ, Stühlinger M et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001;38:111-6.
25. Stühlinger MC, Abbasi F, Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6.
26. Miyazaki H, Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-6.
27. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
28. Halcox JPJ, Schenke WH, Zalos G et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
29. Böger RH, Bode-Böger SM, Tsao PS et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cordiol 2000;36:2287-95.
30. Böger RH, Lentz SR, Bode-Böger SM et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci 2001;100:161-7.
31. Stühtinger MC, Tsao PS, Her JP et al. Homocysteine impairs the nitric oxide synthase pathway: rote of asymmetric dimethylarginine. Circulation 2001;104:2569-75.
32. Brzosko S, Krauze-Brzosko K, de Gaetano G et al. Asymmetrical dimethylarginine and risk of acute coronary events. Lancet 2002;359:1620 (letter).
33. Genser D, Prachar H, Hauer R et al. Relation of homocysteine, vitamin B12, and folate to coronary in-stent restenosis. Am J Cardiol 2002;89:495-9.
34. Schnyder G, Roffi M, Flammer Y et al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002;23:726-33.
35. Zairis MN, Ambrose JA, Manousakis SJ et al. The impact of plasma levels of C-reactive protein, lipoprotein (a), and homocysteine on the tong-term prognosis after successful coronary stenting. J Am Coll Cardiol 2002;40:1375-82.
36. Buffon A, Liuzzo G, Biasucci LM et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cordiol 1999;34:1512-21.
37. Watter DH, Fichtlscherer S, Sellwig M et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cordial 2001;37:839-46.